![](/wp-content/uploads/2018/10/PYravoc8RKimQk5c5T6G.png)
$599
FENIX Analysis: Mounjaro Launch Update
Following approval of Lilly’s Mounjaro (tirzepatide) in T2DM in May 2022 (previous FENIX insight), FENIX has conducted an initial launch analysis, including early insights from prescription trends as well as a look into the Mounjaro promotional, sampling, and copay card tactics.